Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582217 · ClinicalTrials.gov registry record
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 318
- Enrollment target
NCT01582217: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT01582217 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 318 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582217 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 318 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidogrel therapy.
Primary Outcome
Major adverse cardiac events (all-cause death, myocardial infarction and stent thrombosis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-12 |
What the finished NCT01582217 record still lists
NCT01582217 is an observational study that tracks outcomes without assigning an intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01582217 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582217 about?
NCT01582217 is a clinical study titled "Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition". The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidog...
What is the current status of trial NCT01582217?
This trial is currently completed. The enrollment target is 318 participants. The study started on 2012-03. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01582217?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia